

# Closing the Healthcare Gap by Applying Predictive Analytics to Improve the Use of Medicines

Murray Aitken

Executive Director, IMS Institute for Healthcare Informatics

July 27, 2015

For discussion purposes only. Not approved by management. IMS Health Confidential



# About IMS Health

## MISSION

Leverage information and technology services to deliver intelligence and drive improved performance for a growing universe of healthcare customers globally



### Information

**10+** Petabytes of unique data  
**800,000+** data feeds  
**100,000+** data suppliers

**500M+** anonymous patient records  
**6M+** professionals and organizations  
**300,000+** social media sources



### Technology

**55 billion+** transactions p.a.  
**Cloud** based analytics

**Pre integrated** IMS Health data  
**SaaS** applications



### Services

**1,200+** healthcare informatics experts worldwide  
**4,500+** industry and customer experts worldwide  
**5** global operation centers of excellence

# About IMS Institute for Healthcare Informatics

## MISSION

Provide policy setters and decision-makers in the global health sector with unique and transformational insights related to healthcare dynamics derived from granular analysis of information

### Unbiased Information



### Academic Research




### Public Policy Support




# What is the healthcare gap?

---

Clinical and economic dimensions




# For example, the difference between responsible use of medicines and current reality ...




# ... that results in a ~500 Billion USD avoidable cost opportunity annually

Annual magnitude of the opportunity in the health system  
Total \$Bn with minimum and maximum ranges




*This quantification effort is intended to trigger a meaningful discussion on how to assess the impact of responsible medicine use and not on the exact figures*

# Growing availability of Big Data in healthcare



# Non-identified data connecting fragmented healthcare





# The value of predictive analytics

Predictive analytics can help overcome many common limitations of classical statistical methods encountered when analyzing complex data




## Study Feature

Objective

Scientific philosophy

Statistical method  
(examples)

Strengths of approach



## Classical statistics

Understanding associations between variables

Hypothesis-driven / variables pre-specified

Descriptive, regressions

Widely understood; ideal for testing hypotheses; estimate impact of variables



## Predictive analytics


Prediction / knowledge discovery

Data-driven / variable agnostic


Random Forest, Support Vector Machines, Neural Networks

Flexible / powerful; ideal at producing robust evidence in complex settings; prediction accuracy

# The value of predictive analytics is being recognised across healthcare



# Predictive analytics can add value throughout the product lifecycle



# Applying predictive analytics capabilities

## Identifying non-diagnosed patients: Finding new patients for treatments

e.g. rare disease detection, market sizing, physician targeting

## Risk stratification for disease progression

Identify target populations for treatment through prediction of patients most likely to experience disease progression and who stand to gain most from treatment

e.g. identify high risk target groups for prioritized efforts to access



## Treatment response profiling

Increase product understanding, targeting and development through identification of treatment patient responders and non-responders

e.g. identifying target groups for market access, post-launch for product understanding and identifying unmet need

**Each of these analytics offerings can help realize significant health system benefits**

# Identifying Undiagnosed Patients

## OVERVIEW

- Diagnostic algorithms help identify undiagnosed patients
- Algorithms can help find new patients for treatments through:
  - Accelerating time to diagnosis
  - Identifying pockets of untreated patients / physician targeting
  - Detecting patients with rare diseases
- This can be achieved through evidence generation, salesforce targeting or automatic alerts in EMR systems


## IMS STUDY

- A predictive algorithm was developed to identify potentially undiagnosed patients with a rare oncology disease
- Analysis was based on linked primary and secondary-care data
- 350 confirmed cases were identified out of ~3 million patients
- Algorithm development was based on 300 of the confirmed cases and 30k random unconfirmed cases
- The algorithm was validated using the remaining 50 confirmed cases and 70k random unconfirmed cases

## OUTCOMES


- Out of the 70k patients in the validation data, the algorithm identified 270 patients suspected of having the disease, of which:

30 cases had a confirmed diagnosis (60% of the 50 confirmed cases)



240 cases had no confirmed diagnosis - potentially undiagnosed and eligible for treatment

Preliminary results; study on-going.



## 2. Risk stratification for disease progression

### OVERVIEW


- Identifying patients most likely to experience disease progression
- Evidence can support product uptake by identifying types of patients who stand to gain most from treatment
- Published results can inform guideline development
- Predictive algorithm can be built into EMR to facilitate clinical decision-making

### IMS STUDY

- A client has an ophthalmology drug expected to launch shortly
- Payers are unlikely to approve reimbursement for the large indicated population
- The client is interested in identifying patients most likely to progress from mild to advance disease stage
- The evidence can be used to secure reimbursement for targeted patient group

### OUTCOMES

- The model was highly effective at stratifying patients by risk of disease progression<sup>1</sup>
  - Patients were **15 times more likely** to experience disease progression in the **highest compared to lowest strata**
- Key prognostic attributes included number of Optical coherence tomography, number of eye diagnoses and hypertension



Source: IMS RWE Solutions; Advanced Analytics  
IMS Health Confidential



# 3. Treatment response profiling

## OVERVIEW

Identifying treatment responders / non-responders can support:

- Targeted market access strategy focusing on positive responders
- Enhanced product understanding by profiling types of patients who benefit most from treatment
- Assessment of unmet need


## IMS STUDY

- A client with a product in neurology, was concerned about losing market share to an alternative product
- The client wanted to know the profile of patients who were more persistent (adherent) on their product compared to the alternative product
- This evidence could be used for targeted messaging

## OUTCOMES

Analysis was based on uplift models, designed to identify treatment heterogeneity<sup>1</sup>

- On average, the persistence rate was 9% lower for the client product
- However, analysis revealed a sizeable potential target group
- Not only was the persistence rate for the client product high in the target group, it was 8 percentage points higher than for the alternative product
- In relation to all treated patients, the target group was more likely to be male, younger and have fewer co-morbidities.



Source: IMS RWE Solutions; Advanced Analytics

IMS Health Confidential

# Future advancement of predictive analytics

---

## Dependencies for increased value from predictive analytic techniques

Access to data sources

- Connected health data sets
- Genomic data
- Lab values

Advanced analytic tools

- Customization of existing technologies to healthcare-specific challenges

Application to decision-making

- Ease of use
- Widening use by researchers
- Evidence of impact and value